The SCMCIE94 Protocol for Countries With Limited Resources.
作者信息
Cohen Ian J
机构信息
Schneider Children's Medical Center of Israel, Elkanah, Israel.
Tel Aviv University, Tel Aviv, Israel.
出版信息
J Glob Oncol. 2019 Apr;5:1. doi: 10.1200/JGO.19.00044.
Abstract
摘要
相似文献
1
The SCMCIE94 Protocol for Countries With Limited Resources.适用于资源有限国家的SCMCIE94协议。
J Glob Oncol. 2019 Apr;5:1. doi: 10.1200/JGO.19.00044.
2
SCMCIE94: an intensified pilot treatment protocol known to be associated with cure in CD 56-negative non-pelvic isolated Ewing sarcoma (EWS) is also associated with no early relapses in non-metastatic extremity EWS.SCMCIE94：一种强化的试验性治疗方案，已知与 CD56 阴性非盆腔孤立性尤因肉瘤（EWS）的治愈相关，也与非转移性肢体 EWS 无早期复发相关。
Cancer Chemother Pharmacol. 2019 May;83(5):859-866. doi: 10.1007/s00280-019-03789-3. Epub 2019 Feb 15.
3
Outcome of Ewing sarcoma in a multidisciplinary setting in Lebanon.黎巴嫩多学科环境下尤文肉瘤的治疗结果。
Pediatr Blood Cancer. 2014 Aug;61(8):1472-5. doi: 10.1002/pbc.24926. Epub 2014 Jan 7.
4
Carboplatin in the treatment of Ewing sarcoma: Results of the first Brazilian collaborative study group for Ewing sarcoma family tumors-EWING1.卡铂治疗尤因肉瘤：巴西首个尤因肉瘤家族性肿瘤协作研究组-EWING1的研究结果
Pediatr Blood Cancer. 2015 Oct;62(10):1747-53. doi: 10.1002/pbc.25562. Epub 2015 Apr 27.
5
Validation of a multi-modal treatment protocol for Ewing sarcoma--a report from the polish pediatric oncology group.尤因肉瘤多模式治疗方案的验证——来自波兰儿科肿瘤学组的报告
Pediatr Blood Cancer. 2014 Dec;61(12):2170-4. doi: 10.1002/pbc.25167. Epub 2014 Aug 27.
6
Phase II study of intermediate-dose cytarabine in patients with relapsed or refractory Ewing sarcoma: a report from the Children's Oncology Group.复发或难治性尤因肉瘤患者中剂量阿糖胞苷的II期研究：来自儿童肿瘤学组的报告
Pediatr Blood Cancer. 2009 Mar;52(3):324-7. doi: 10.1002/pbc.21822.
7
High-throughput tyrosine kinase activity profiling identifies FAK as a candidate therapeutic target in Ewing sarcoma.高通量酪氨酸激酶活性分析鉴定黏着斑激酶为尤文肉瘤的候选治疗靶点。
Cancer Res. 2013 May 1;73(9):2873-83. doi: 10.1158/0008-5472.CAN-12-1944. Epub 2013 Mar 27.
8
Primary cutaneous Ewing sarcoma: a systematic review focused on treatment and outcome.原发性皮肤尤文肉瘤：一项侧重于治疗和结局的系统评价。
Br J Dermatol. 2012 Apr;166(4):721-6. doi: 10.1111/j.1365-2133.2011.10743.x. Epub 2012 Mar 5.
9
New Resources and Strategies to Advance the AAP's Values of Diversity, Inclusion, and Health Equity.推进美国儿科学会多元化、包容性和健康公平价值观的新资源与策略。
Pediatrics. 2018 Apr;141(4). doi: 10.1542/peds.2018-0177. Epub 2018 Mar 19.
10
Impact of the Interdisciplinary Tumor Board of the Cooperative Ewing Sarcoma Study Group on local therapy and overall survival of Ewing sarcoma patients after induction therapy.合作尤文肉瘤研究组多学科肿瘤委员会对诱导治疗后尤文肉瘤患者局部治疗和总生存的影响。
Pediatr Blood Cancer. 2018 Dec;65(12):e27384. doi: 10.1002/pbc.27384. Epub 2018 Aug 7.
本文引用的文献
1
SCMCIE94: an intensified pilot treatment protocol known to be associated with cure in CD 56-negative non-pelvic isolated Ewing sarcoma (EWS) is also associated with no early relapses in non-metastatic extremity EWS.SCMCIE94：一种强化的试验性治疗方案，已知与 CD56 阴性非盆腔孤立性尤因肉瘤（EWS）的治愈相关，也与非转移性肢体 EWS 无早期复发相关。
Cancer Chemother Pharmacol. 2019 May;83(5):859-866. doi: 10.1007/s00280-019-03789-3. Epub 2019 Feb 15.
2
Treatment Outcomes of Pediatric Patients With Ewing Sarcoma in a War-Torn Nation: A Single-Institute Experience From Iraq.一个饱受战争蹂躏国家的尤因肉瘤儿科患者的治疗结果：来自伊拉克的单机构经验。
J Glob Oncol. 2019 Jan;5:1-9. doi: 10.1200/JGO.18.00122.
Zotero 插件